Nrx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with central nervous system disorders and critical medical conditions
The company is dedicated to addressing unmet medical needs through its research and development efforts, particularly in the areas of depression, anxiety, and other severe neuropsychiatric conditions. Nrx Pharmaceuticals' approach integrates cutting-edge science with a commitment to improving patient outcomes, leveraging both established and novel treatment modalities to better serve those affected by complex health challenges.
NRX shares are trading higher on Thursday after the company announced a joint acquisition initiative with Hope Therapeutics to buy Kadima Neuropsychiatry Institute.
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.34% to 37,880.89 while the NASDAQ fell 0.16% to 15,658.94. The S&P 500 also rose, gaining, 0.03% to 5,023.87.
